The FINANCIAL – Novo Nordisk published financial report for the period 1 January 2020 to 30 September 2020 Sales increased by 6% in Danish kroner and by 7% at CER to DKK 94.8 billion. Sales in International Operations increased by 9% in Danish kroner (12% at CER), and sales in North America Operations increased by 2% in Danish kroner (2% at CER). Sales growth was negatively impacted by COVID-19 as fewer patients initiated treatment, partially offset by COVID-19-related stocking in the first quarter. Sales within Diabetes and Obesity care increased by 6% to DKK 80.3 billion (8% at CER), driven…
Read More »The FINANCIAL – Novo Nordisk published financial report for the period 1 January 2020 to 30 September 2020 Sales increased by 6% in Danish kroner and by 7% at CER to DKK 94.8 billion. Sales in International Operations increased by 9% in Danish kroner (12% at CER), and sales in North America Operations increased by…
You might be interested in
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index…
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…
The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies…